site stats

Syros tyme technologies

WebSep 15, 2024 · Syros Pharmaceuticals, Inc. SYRS, a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. TYME today announced the results of the special ... WebSep 15, 2024 · CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2024 (GLOBE NEWSWIRE) -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders …

Syros and Tyme Technologies Announce Stockholder Approval of …

WebJul 5, 2024 · Per the terms, Syros ( SYRS) will issue ~74.3M shares of its common stock to TYME investors, and TYME stockholders are entitled to nearly 0.4312 shares of Syros ( SYRS) common stock for... WebSep 15, 2024 · Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2024. free new living bible audio https://hotel-rimskimost.com

Syros Merges with TYME Technologies, Raises $190 Million in a …

WebJun 28, 2024 · TYME (Nasdaq: TYME), an innovative biotechnology company leveraging novel and data-driven approaches to develop therapeutics for difficult to treat cancers. Science & Technology Bedminster, NJ 07921 tymeinc.com Joined June 2024. 1,200 Following. 1,157 Followers. WebNov 14, 2024 · In September, Syros announced the closing of its merger with TYME Technologies, pursuant to which Syros acquired TYME, including its pipeline assets and net cash at closing of approximately $60 million. Concurrent with the closing of the merger, Syros also closed the previously announced oversubscribed $130 million private … WebJul 5, 2024 · Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros … farley\\u0027s menu

Syros Announces Closing of Merger with Tyme Technologies and Conc…

Category:Syros to Raise Approximately $190 Million Through Merger with TYME …

Tags:Syros tyme technologies

Syros tyme technologies

Syros, Tyme Technologies Shares Rise After Hldrs Approve Merger

WebJul 5, 2024 · In the merger, Syros expects to issue approximately 74.3 million shares of its common stock to TYME stockholders to acquire TYME’s expected net cash at closing and … WebApr 10, 2024 · Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. …

Syros tyme technologies

Did you know?

WebTYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™) that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients’ quality of life through relatively low toxicity profiles. WebAug 9, 2024 · CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2024 and provided a corporate update.

WebBy merging with the floundering Tyme Technologies and tapping investors including Flagship Pioneering, the gene expression biotech has extended its cash runway out into 2025. Syros buys Tyme ... WebJul 5, 2024 · Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement Business Wire July 5, 2024, 4:00 AM · 16 …

WebSep 15, 2024 · Shareholders of Syros Pharmaceuticals (SYRS) and Tyme Technologies (TYME) on Thursday voted in favor of the merger between the two biotech companies.SYRS and TYME stock gained more... WebSep 15, 2024 · CAMBRIDGE, Mass. & BEDMINSTER, N.J., September 15, 2024--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme ...

WebJul 5, 2024 · CAMBRIDGE, Mass. & BEDMINSTER, N.J.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NASDAQ:TYME), today announced that the companies have entered into a definitive merger agreement pursuant to which Syros …

WebJul 5, 2024 · Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros' Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data farley\u0027s menuWebSep 16, 2024 · CAMBRIDGE, Mass., September 16, 2024 -- ( BUSINESS WIRE )--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that … farley\\u0027s martial arts visalia cafarley\u0027s menswearWebSyros Pharmaceuticals is set to acquire a New Jersey biotech firm called Tyme Technologies Inc., extending its cash runway into 2025 at a time when biotech stocks are … farley\u0027s martial artsWebSep 15, 2024 · Syros and Tyme Technologies Announce Stockholder Approval of Merger TYME Technologies, Inc. September 15, 2024, 4:13 PM · 10 min read TYME Technologies, … farley\u0027s martial arts visalia caWebAbout Tyme Technologies, Inc. TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™) that are intended to be effective across a … free newman kitWebJul 5, 2024 · Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement July 5, 2024, 7:00 AM · 16 min read Combined Company Will Operate as Syros... freenewmankit.com